A J Conde-Moreno, F Lopez, A Hervas, V Morillo, A Mendez, M D M Puertas, J Valero Albarrán, A Gomez De Iturriaga, M Rico, M L Vázquez de la Torre, P M Samper Ots, L A Perez Romasanta, J Pastor Peidro, C Ibañez, F Ferrer, A Zapatero, J Anchuelo, A Rodriguez, C F Albiach
PURPOSE/OBJECTIVE(S): SBRT-SG 05 is a collaborative (SBRT-SG, GICOR and SEOR) prospective multicenter phase II trial testing SBRT and androgen deprivation therapy (ADT) in oligorecurrent prostate cancer patients. MATERIALS/METHODS: Prostate cancer patients (hormone-sensitive or castration-resistant) in an oligorecurrent stage defined as less than 5 bone or lymph node metastases by Choline PET-CT or/and WB-DWI-MRI, after primary treatment, were assigned to receive ADT and SBRT (Vertebral metastases: 1 × 16-18Gy or 3 × 8-9Gy; lymph node metastases: 3 × 10-11 Gy or 6 × 7,5Gy; non-spinal bone metastases: 1 × 16Gy or 3 × 10Gy)...
November 1, 2021: International Journal of Radiation Oncology, Biology, Physics